Literature DB >> 27586003

Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia.

Yen Ying Lim1, Victor L Villemagne2,3,4, Simon M Laws5,6,7, Robert H Pietrzak8, David Ames9,10, Christopher Fowler2, Stephanie Rainey-Smith5, Peter J Snyder11, Pierrick Bourgeat12, Ralph N Martins5, Olivier Salvado12, Christopher C Rowe3,4, Colin L Masters2, Paul Maruff2,13.   

Abstract

In a group of older adults with very mild dementia, we aimed to characterize the nature and magnitude of cognitive decline as measured by the Cogstate Brief Battery, in relation to Aβ levels and hippocampal volume. Participants were characterized according to their status on the Clinical Dementia Rating (CDR) scale. A total of 308 individuals who were CDR 0 and had low cerebral Aβ levels (Aβ-), 32 individuals who were Aβ- and CDR 0.5, and 43 individuals who were Aβ+ and CDR 0.5 were included in this study. Participants completed the CogState brief battery at baseline, and at 18-, 36-, 54- and 72-month follow-up. Linear mixed model analyses indicated that relative to the Aβ- CDR 0 group, the Aβ+ CDR 0.5 group showed increased rates of memory decline and hippocampal volume loss. However, compared to the Aβ- CDR 0 group, the Aβ- CDR 0.5 group showed no changes in cognitive function or hippocampal volume over 72 months. The results of this study confirm that in individuals with very mild dementia, who also have biomarker confirmation of Aβ+, changes in cognitive function manifest primarily as deterioration in memory processing, and this is associated with hippocampal volume loss. Conversely, the absence of any cognitive decline or loss in hippocampal volume in individuals with very mild dementia but who are Aβ- suggests that some other non-AD disease process may underlie any static impairment in cognitive function.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid; Hippocampal volume; Memory; Mild dementia

Mesh:

Substances:

Year:  2016        PMID: 27586003     DOI: 10.1007/s12031-016-0822-8

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  29 in total

1.  APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Authors:  John C Morris; Catherine M Roe; Chengjie Xiong; Anne M Fagan; Alison M Goate; David M Holtzman; Mark A Mintun
Journal:  Ann Neurol       Date:  2010-01       Impact factor: 10.422

2.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Authors:  Anne M Fagan; Catherine M Roe; Chengjie Xiong; Mark A Mintun; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2007-01-08

3.  18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

Authors:  Rik Vandenberghe; Koen Van Laere; Adrian Ivanoiu; Eric Salmon; Christine Bastin; Eric Triau; Steen Hasselbalch; Ian Law; Allan Andersen; Alex Korner; Lennart Minthon; Gaëtan Garraux; Natalie Nelissen; Guy Bormans; Chris Buckley; Rikard Owenius; Lennart Thurfjell; Gill Farrar; David J Brooks
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

4.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

Review 5.  Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: insights from functional MRI studies.

Authors:  Bradford C Dickerson; Reisa A Sperling
Journal:  Neuropsychologia       Date:  2007-12-08       Impact factor: 3.139

6.  Neuropathology of cognitively normal elderly.

Authors:  D S Knopman; J E Parisi; A Salviati; M Floriach-Robert; B F Boeve; R J Ivnik; G E Smith; D W Dickson; K A Johnson; L E Petersen; W C McDonald; H Braak; R C Petersen
Journal:  J Neuropathol Exp Neurol       Date:  2003-11       Impact factor: 3.685

7.  Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.

Authors:  Vincent Doré; Victor L Villemagne; Pierrick Bourgeat; Jurgen Fripp; Oscar Acosta; Gael Chetélat; Luping Zhou; Ralph Martins; Kathryn A Ellis; Colin L Masters; David Ames; Oliver Salvado; Christopher C Rowe
Journal:  JAMA Neurol       Date:  2013-07       Impact factor: 18.302

8.  Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community.

Authors:  Ronald C Petersen; Heather J Wiste; Stephen D Weigand; Walter A Rocca; Rosebud O Roberts; Michelle M Mielke; Val J Lowe; David S Knopman; Vernon S Pankratz; Mary M Machulda; Yonas E Geda; Clifford R Jack
Journal:  JAMA Neurol       Date:  2016-01       Impact factor: 18.302

Review 9.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

10.  Amnestic MCI or prodromal Alzheimer's disease?

Authors:  Bruno Dubois; Martin L Albert
Journal:  Lancet Neurol       Date:  2004-04       Impact factor: 44.182

View more
  12 in total

1.  Validation of online functional measures in cognitively impaired older adults.

Authors:  Rachel L Nosheny; Monica R Camacho; Chengshi Jin; John Neuhaus; Diana Truran; Derek Flenniken; Miriam Ashford; Maria C Carrillo; Keith N Fargo; James Hendrix; Lucy Hanna; Gil Rabinovici; Paul Maruff; R Scott Mackin; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2020-07-27       Impact factor: 21.566

2.  Dementia Research Australia: the Australian Dementia Research Development Fellowship Program.

Authors:  Ashley I Bush; George Fink; Peng Lei
Journal:  J Mol Neurosci       Date:  2016-11       Impact factor: 3.444

3.  Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.

Authors:  Elizabeth C Mormino; Kathryn V Papp; Dorene M Rentz; Michael C Donohue; Rebecca Amariglio; Yakeel T Quiroz; Jasmeer Chhatwal; Gad A Marshall; Nancy Donovan; Jonathan Jackson; Jennifer R Gatchel; Bernard J Hanseeuw; Aaron P Schultz; Paul S Aisen; Keith A Johnson; Reisa A Sperling
Journal:  Alzheimers Dement       Date:  2017-02-28       Impact factor: 21.566

4.  Digital Cognitive Assessments for Dementia: Digital assessments may enhance the efficiency of evaluations in neurology and other clinics.

Authors:  Adam M Staffaroni; Elena Tsoy; Jack Taylor; Adam L Boxer; Katherine L Possin
Journal:  Pract Neurol (Fort Wash Pa)       Date:  2020 Nov-Dec

5.  Unsupervised assessment of cognition in the Healthy Brain Project: Implications for web-based registries of individuals at risk for Alzheimer's disease.

Authors:  Stephanie Perin; Rachel F Buckley; Matthew P Pase; Nawaf Yassi; Alexandra Lavale; Peter H Wilson; Adrian Schembri; Paul Maruff; Yen Ying Lim
Journal:  Alzheimers Dement (N Y)       Date:  2020-06-26

6.  Muscle strength and gait speed rather than lean mass are better indicators for poor cognitive function in older men.

Authors:  Sophia X Sui; Kara L Holloway-Kew; Natalie K Hyde; Lana J Williams; Sarah Leach; Julie A Pasco
Journal:  Sci Rep       Date:  2020-06-25       Impact factor: 4.379

7.  Unsupervised online neuropsychological test performance for individuals with mild cognitive impairment and dementia: Results from the Brain Health Registry.

Authors:  R Scott Mackin; Philip S Insel; Diana Truran; Shannon Finley; Derek Flenniken; Rachel Nosheny; Aaron Ulbright; Monica Comacho; David Bickford; Brian Harel; Paul Maruff; Michael W Weiner
Journal:  Alzheimers Dement (Amst)       Date:  2018-06-21

8.  Associating Cognition With Amyloid Status Using Partially Ordered Set Analysis.

Authors:  Sarah J A Carr; Judith Jaeger; Shijia Bian; Ping He; Nancy Maserejian; Wenting Wang; Paul Maruff; Ahmed Enayetallah; Yanming Wang; Zhengyi Chen; Alan Lerner; Curtis Tatsuoka
Journal:  Front Neurol       Date:  2019-09-13       Impact factor: 4.003

9.  Skeletal Muscle Density and Cognitive Function: A Cross-Sectional Study in Men.

Authors:  Sophia X Sui; Lana J Williams; Kara L Holloway-Kew; Natalie K Hyde; Kara B Anderson; Monica C Tembo; Alex B Addinsall; Sarah Leach; Julie A Pasco
Journal:  Calcif Tissue Int       Date:  2020-09-27       Impact factor: 4.333

10.  Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease.

Authors:  Christopher Fowler; Stephanie R Rainey-Smith; Sabine Bird; Julia Bomke; Pierrick Bourgeat; Belinda M Brown; Samantha C Burnham; Ashley I Bush; Carolyn Chadunow; Steven Collins; James Doecke; Vincent Doré; Kathryn A Ellis; Lis Evered; Amir Fazlollahi; Jurgen Fripp; Samantha L Gardener; Simon Gibson; Robert Grenfell; Elise Harrison; Richard Head; Liang Jin; Adrian Kamer; Fiona Lamb; Nicola T Lautenschlager; Simon M Laws; Qiao-Xin Li; Lucy Lim; Yen Ying Lim; Andrea Louey; S Lance Macaulay; Lucy Mackintosh; Ralph N Martins; Paul Maruff; Colin L Masters; Simon McBride; Lidija Milicic; Madeline Peretti; Kelly Pertile; Tenielle Porter; Morgan Radler; Alan Rembach; Joanne Robertson; Mark Rodrigues; Christopher C Rowe; Rebecca Rumble; Olivier Salvado; Greg Savage; Brendan Silbert; Magdalene Soh; Hamid R Sohrabi; Kevin Taddei; Tania Taddei; Christine Thai; Brett Trounson; Regan Tyrrell; Michael Vacher; Shiji Varghese; Victor L Villemagne; Michael Weinborn; Michael Woodward; Ying Xia; David Ames
Journal:  J Alzheimers Dis Rep       Date:  2021-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.